SIX1 Is Overexpressed in Endometrial Carcinoma and Promotes the Malignant Behavior of Cancer?cells Through ERK and AKT Signaling

Oncology Letters - Greece
doi 10.3892/ol.2016.5098
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Six1 Promotes Proliferation and Migration of Human Colorectal Cancer Cells Through Activating WNT/Β‐catenin Signaling

Cancer Science
Cancer ResearchMedicineOncology
2019English

STYK1 Promotes Epithelial-Mesenchymal Transition and Tumor Metastasis in Human Hepatocellular Carcinoma Through MEK/ERK and PI3K/AKT Signaling

Scientific Reports
Multidisciplinary
2016English

Glypican-3 Promotes Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells Through ERK Signaling Pathway

International Journal of Oncology
Cancer ResearchOncology
2015English

Overexpression of IQGAP1 Promotes the Angiogenesis of Esophageal Squamous Cell Carcinoma Through the AKT and ERK‑mediated VEGF‑VEGFR2 Signaling Pathway

Oncology Reports
MedicineCancer ResearchOncology
2018English

CAFs-derived MFAP5 Promotes Bladder Cancer Malignant Behavior Through NOTCH2/HEY1 Signaling

FASEB Journal
BiochemistryBiotechnologyGeneticsMolecular BiologyMedicine
2020English

Hydrogen Sulfide Promotes Autophagy of Hepatocellular Carcinoma Cells Through the PI3K/Akt/mTOR Signaling Pathway

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2017English

ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways

PLoS ONE
Multidisciplinary
2010English

DOK7V1 Influences the Malignant Phenotype of Lung Cancer Cells Through PI3K/AKT/mTOR and FAK/paxillin Signaling Pathways

International Journal of Oncology
Cancer ResearchOncology
2018English

E2F3 Promotes Cancer Growth and Is Overexpressed Through Copy Number Variation in Human Melanoma

OncoTargets and Therapy
OncologyPharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy